PG
MACK

PEAK6 Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

PEAK6 Group’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-604
Closed -$56K – 5782
2015
Q1 		$56K Buy
+604
New +$51.4K ﹤0.01% 4222

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

PEAK6 Group's MACK Position: Q2 2015 in Review

PEAK6 Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2015, closing a stake of 604 shares — an estimated $56K sold.

PEAK6 Group first reported a position in MACK in Q1 2015 and held it in 1 quarter. The position peaked at $56K in Q1 2015. 150 funds tracked by Wall St. Rank hold MACK as of Q2 2015.

  • PEAK6 Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • PEAK6 Group sold 604 Merrimack Pharmaceuticals, Inc. shares in Q2 2015, an estimated $56K.
  • PEAK6 Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • PEAK6 Group's Merrimack Pharmaceuticals, Inc. position peaked at $56K in Q1 2015.
  • 150 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2015.

Based on PEAK6 Group's 13F filing for Q2 2015, filed 11 Aug 2015.